On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...